Safety and Efficacy of Switching Patients With Type 2 Diabetes From Glucagon-Like Peptide-1 Receptor Agonists to Tirzepatide: A Case Series.

IF 0.8 Q4 PHARMACOLOGY & PHARMACY Hospital Pharmacy Pub Date : 2024-12-01 Epub Date: 2024-08-05 DOI:10.1177/00185787241266803
Sami Barakat, Shannon Ramdeen, Rebecca Khaimova
{"title":"Safety and Efficacy of Switching Patients With Type 2 Diabetes From Glucagon-Like Peptide-1 Receptor Agonists to Tirzepatide: A Case Series.","authors":"Sami Barakat, Shannon Ramdeen, Rebecca Khaimova","doi":"10.1177/00185787241266803","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Tirzepatide is a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (RA) that is approved for the treatment of type 2 diabetes mellitus (T2D). Despite its similarities to GLP-1 RA, there is a lack of data on how to switch between GLP-1 RA and GIP/GLP-1 RA. <b>Objectives:</b> The objective of this study is to evaluate the efficacy and safety of switching from GLP-1 RA to tirzepatide in patients with T2D and provide guidance for switching between the two classes. <b>Methods:</b> This was a retrospective case series of patients with T2D who met protocol criteria for switching between the two classes. Hemoglobin A1C (A1C) and weight data were evaluated at 3 and 6 months. <b>Results:</b> A total of 10 patients were included. Mean change from baseline in A1C was -0.7 ± 0.9% at 3 months (N = 8) compared to -1.4 ± 0.7% at 6 months (N = 4). Percentage of patients who achieved their goal A1C was 25% (2/8) at 3 months post switch compared to 50% (2/4) at 6 months. Mean change from baseline in weight was -3.6 ± 2.3 kg at 3 months and -6 ± 3.4 kg at 6 months. Percentage of patients who achieved weight loss from baseline of ≥10% was 0 at 3 months versus 33.3% (1/3) at 6 months. Few adverse events were reported after switching. <b>Conclusion:</b> Switching can be considered for patients with T2D that require further A1C and weight reduction to reach their target goals despite being on GLP-1 RA.</p>","PeriodicalId":13002,"journal":{"name":"Hospital Pharmacy","volume":"59 6","pages":"614-619"},"PeriodicalIF":0.8000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11497530/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hospital Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/00185787241266803","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/5 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Tirzepatide is a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (RA) that is approved for the treatment of type 2 diabetes mellitus (T2D). Despite its similarities to GLP-1 RA, there is a lack of data on how to switch between GLP-1 RA and GIP/GLP-1 RA. Objectives: The objective of this study is to evaluate the efficacy and safety of switching from GLP-1 RA to tirzepatide in patients with T2D and provide guidance for switching between the two classes. Methods: This was a retrospective case series of patients with T2D who met protocol criteria for switching between the two classes. Hemoglobin A1C (A1C) and weight data were evaluated at 3 and 6 months. Results: A total of 10 patients were included. Mean change from baseline in A1C was -0.7 ± 0.9% at 3 months (N = 8) compared to -1.4 ± 0.7% at 6 months (N = 4). Percentage of patients who achieved their goal A1C was 25% (2/8) at 3 months post switch compared to 50% (2/4) at 6 months. Mean change from baseline in weight was -3.6 ± 2.3 kg at 3 months and -6 ± 3.4 kg at 6 months. Percentage of patients who achieved weight loss from baseline of ≥10% was 0 at 3 months versus 33.3% (1/3) at 6 months. Few adverse events were reported after switching. Conclusion: Switching can be considered for patients with T2D that require further A1C and weight reduction to reach their target goals despite being on GLP-1 RA.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
2 型糖尿病患者从胰高血糖素样肽-1 受体激动剂转用替扎帕肽的安全性和有效性:病例系列。
背景:替扎帕肽是一种新型葡萄糖依赖性促胰岛素多肽(GIP)和胰高血糖素样肽-1(GLP-1)受体激动剂(RA),已被批准用于治疗 2 型糖尿病(T2D)。尽管它与 GLP-1 RA 相似,但目前缺乏有关如何在 GLP-1 RA 和 GIP/GLP-1 RA 之间切换的数据。研究目的本研究旨在评估 T2D 患者从 GLP-1 RA 转用替扎帕肽的疗效和安全性,并为这两类药物之间的转换提供指导。研究方法这是一项回顾性病例系列研究,研究对象为符合两类药物转换方案标准的 T2D 患者。在 3 个月和 6 个月时评估血红蛋白 A1C (A1C) 和体重数据。结果:共纳入 10 名患者。3 个月时,A1C 与基线相比的平均变化率为 -0.7 ± 0.9%(8 人),而 6 个月时,A1C 与基线相比的平均变化率为 -1.4 ± 0.7%(4 人)。换药后 3 个月达到目标 A1C 的患者比例为 25%(2/8),而 6 个月时为 50%(2/4)。与基线相比,3 个月时体重的平均变化为 -3.6 ± 2.3 千克,6 个月时为 -6 ± 3.4 千克。体重从基线下降≥10%的患者比例在3个月时为0,而在6个月时为33.3%(1/3)。换药后很少出现不良反应。结论尽管服用了 GLP-1 RA,但仍需要进一步降低 A1C 和减轻体重以达到目标的 T2D 患者可以考虑换药。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Hospital Pharmacy
Hospital Pharmacy PHARMACOLOGY & PHARMACY-
CiteScore
1.70
自引率
0.00%
发文量
63
期刊介绍: Hospital Pharmacy is a monthly peer-reviewed journal that is read by pharmacists and other providers practicing in the inpatient and outpatient setting within hospitals, long-term care facilities, home care, and other health-system settings The Hospital Pharmacy Assistant Editor, Michael R. Cohen, RPh, MS, DSc, FASHP, is author of a Medication Error Report Analysis and founder of The Institute for Safe Medication Practices (ISMP), a nonprofit organization that provides education about adverse drug events and their prevention.
期刊最新文献
Cefepime/Enmetazobactam. Impact of a Medication Reconciliation Improvement Package on Adherence to Medication Reconciliation Among Internal Medicine Physicians: A Quality Improvement Project in a Lower-Middle Income Country. Implementing Research Into Practice as a Clinical Based New Practitioner Pharmacist. Phytonadione Utilization and the Risk of Bleeding in Chronic Liver Disease. Safety and Efficacy of Switching Patients With Type 2 Diabetes From Glucagon-Like Peptide-1 Receptor Agonists to Tirzepatide: A Case Series.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1